Walter M. Stadler to Matrix Metalloproteinase Inhibitors
This is a "connection" page, showing publications Walter M. Stadler has written about Matrix Metalloproteinase Inhibitors.
Connection Strength
0.068
-
A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases. Clin Cancer Res. 2006 Mar 01; 12(5):1556-63.
Score: 0.068